Summit Therapeutics Reports Positive Phase III Lung Cancer Data and $500M Offering
Summit Therapeutics announced positive Phase III HARMONi-6 trial results for ivonescimab in advanced squamous NSCLC, showing a 34% reduction in death risk and median OS of 27.89 months. The company also presented Phase II colorectal cancer data with a 70.8% response rate. Concurrently, Summit raised $500 million in a public offering. The findings were published in The Lancet and presented at ASCO. Global Phase III HARMONi-3 results are expected in late 2026.
Cross-source coverage
Wire timeline
Summit Therapeutics Raises $500 Million in Public Offering, Reports Positive Lung Cancer Trial Data
Summit Therapeutics Inc. (NASDAQ: SMMT) announced a $500 million underwritten public offering of common stock on June 10, 2026, with J.P. Morgan, Goldman Sachs, and Citigroup as joint book-running managers. The company also reported positive Phase 3 HARMONi-6 trial results for ivonescimab combined with chemotherapy as a first-line treatment for squamous non-small cell lung cancer (NSCLC), showing a median progression-free survival of 11 months and a hazard ratio of 0.60. Cantor Fitzgerald reaffirmed its Overweight rating following the data presentation at an ASCO plenary session. Summit is a clinical-stage biopharma focused on developing ivonescimab, a bispecific antibody targeting PD-1 and anti-angiogenesis. The company awaits results from the global Phase 3 HARMONi-3 trial, expected in the second half of 2026.
Yahoo FinanceSummit Therapeutics Raises $500 Million Through Public Offering
Summit Therapeutics Inc. (NASDAQ:SMMT) initiated a $500 million underwritten public offering of common stock on June 10, 2026, with J.P. Morgan, Goldman Sachs & Co., and Citigroup serving as joint book-running managers. The company is a clinical-stage biopharma focused on developing ivonescimab, a bispecific antibody targeting PD-1 and anti-angiogenesis for non-small cell lung cancer (NSCLC). On June 1, following Phase 3 HARMONi-6 trial data presented at an ASCO plenary session, Cantor Fitzgerald reaffirmed its Overweight rating. The trial evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for squamous NSCLC in China, showing median progression-free survival of 11 months and a hazard ratio of 0.60. Interim overall survival data addressed concerns about PFS-to-OS benefit translation. Results from the global Phase 3 HARMONi-3 trial are expected in the second half of 2026.
Yahoo FinanceSummit Therapeutics Reveals Phase II AK112-206 Trial Data for Ivonescimab in Colorectal Cancer
Summit Therapeutics Inc. (NASDAQ: SMMT) presented new clinical data from the international Phase II AK112-206 trial at the American Society of Clinical Oncology on May 31, 2026. The study, co-sponsored with Akeso, evaluates ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with standard mFOLFOX6 chemotherapy for first-line metastatic colorectal cancer. Treatment-naive patients in the U.S. and China showed a strong objective response rate of 70.8%, compared favorably to standard-of-care regimens combining bevacizumab with FOLFOX. On May 1, Piper Sandler cut the price target from $17 to $16, retaining a Neutral rating, noting that shares are 'understandably weak' as investors question whether the effect size seen in Akeso's HARMONi-6 trial can be replicated in Summit's global HARMONi-3 trial. Summit is a clinical-stage biopharma company focused on developing ivonescimab and is also running Phase III trials for non-small cell lung cancer.
Yahoo FinanceSummit Therapeutics Reveals Phase II AK112-206 Trial Data for Ivonescimab in Colorectal Cancer
On May 31, 2026, Summit Therapeutics Inc. (NASDAQ: SMMT) presented new clinical data from the international Phase II AK112-206 trial at the American Society of Clinical Oncology. Co-sponsored with Akeso, the study evaluates ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, for first-line metastatic colorectal cancer. Treatment-naive patients in the U.S. and China receiving ivonescimab combined with standard mFOLFOX6 chemotherapy showed a strong objective response rate of 70.8%, compared favorably to standard-of-care regimens using bevacizumab with FOLFOX. On May 1, Piper Sandler cut the price target on Summit from $17 to $16, retaining a Neutral rating. The company's Q1 earnings report indicated that the projected Q2 preliminary PFS analysis was completed and approved by the IDMC, allowing the research to proceed. Summit shares were described as 'understandably weak' after-hours as investors question whether the effect size seen in Akeso's HARMONi-6 trial can be replicated in Summit's global HARMONi-3 trial.
Yahoo FinanceSummit Therapeutics Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC
Summit Therapeutics (NASDAQ: SMMT) announced positive Phase III overall survival results from the HARMONi-6 trial evaluating ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC). The study showed the ivonescimab regimen reduced the risk of death by 34% (HR 0.66), marking the first time a Phase III trial has demonstrated a statistically significant OS benefit over standard PD-(L)1 inhibitor and chemotherapy combinations in the first-line setting. At a median follow-up of 21.4 months, patients receiving ivonescimab achieved a median OS of 27.89 months compared to 23.69 months for the tislelizumab regimen. The benefit was consistent across PD-L1 expression subgroups, and the 24-month OS rate reached 64.7% for the ivonescimab arm. The findings were simultaneously published in The Lancet. Ivonescimab maintained an acceptable and manageable safety profile with no new safety signals. The article also notes SMMT is considered a high short interest stock with upside potential.
Yahoo Finance